Predicted Trait | |
Reported Trait | Prostate cancer |
Mapped Trait(s) | prostate carcinoma (EFO_0001663) |
Score Construction | |
PGS Name | PrCa66 |
Variants | |
Original Genome Build | GRCh38 |
Number of Variants | 66 |
Development Method | |
Name | Known susceptibility loci (genome-wide significant SNPs) |
Parameters | P-value < 5E-8, top SNP |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000031 |
Citation (link to publication) | Pashayan N et al. Br J Cancer (2015) |
Study Identifiers | Sample Numbers | Sample Ancestry |
---|---|---|
GWAS Catalog: GCST001942 EuropePMC: 23535732 |
22,548 individuals | European |
GWAS Catalog: GCST001148 EuropePMC: 21743467 |
13,560 individuals | European |
GWAS Catalog: GCST000153 EuropePMC: 18264098 |
23,226 individuals | European |
GWAS Catalog: GCST000488 EuropePMC: 19767753 |
3,748 individuals | European |
GWAS Catalog: GCST000750 EuropePMC: 20676098 |
4,969 individuals | East Asian |
GWAS Catalog: GCST001147 EuropePMC: 21743057 |
7,240 individuals | European |
GWAS Catalog: GCST000152 EuropePMC: 18264097 |
3,748 individuals | European |
GWAS Catalog: GCST000489 EuropePMC: 19767754 |
37,350 individuals | European |
GWAS Catalog: GCST000154 EuropePMC: 18264096 |
2,329 individuals | European |
GWAS Catalog: GCST000019 EuropePMC: 17401366 |
4,517 individuals | European |
GWAS Catalog: GCST000017 EuropePMC: 17401363 |
2,329 individuals | European |
GWAS Catalog: GCST001702 EuropePMC: 23023329 |
2,425 individuals | East Asian |
GWAS Catalog: GCST000128 EuropePMC: 18073375 |
2,834 individuals | European |
GWAS Catalog: GCST001714 EuropePMC: 23065704 |
22,548 individuals | European |
PGS Performance Metric ID (PPM ID) |
PGS Sample Set ID (PSS ID) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
PGS Classification Metrics | Other Metrics | Covariates Included in the Model | PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM000105 | PSS000069 | PGP000032 Pashayan N et al. (2015) Ext. | Reported Trait: aggressive prostate cancer (Gleason score ⩾7) | — | — | OR (above vs. below 50th percentile of PRS): 1.56 [1.15, 2.1] | — | — |
PPM000104 | PSS000068 | PGP000031 Pashayan N et al. (2015) | Reported Trait: Elevated serum prostate-specific antigen (PSA) levels | — | — | OR (per 1-point increase in PRS): 1.23 [1.1, 1.37] | cancer stage, Gleason score | — |
PGS Sample Set ID (PSS ID) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS000068 | Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml. | — | [ ,
100.0 % Male samples |
Range = [50.0, 60.0] years | European | — | UKGPCS | — |
PSS000069 | Prostate cancer was classified as localised disease with tumour-node-metastasis (TNM) stage T1-2 N0 M0; and advanced disease (regional-distant) with stage T3 and above or any T N1 M1; as non-aggressive tumour, Gleason score <7, and aggressive tumour, Gleason score ⩾7. | Median = 13.0 years | [ ,
100.0 % Male samples |
Range = [55.0, 71.0] years | European (Finnish) |
— | ERSPC | — |
PSS000068 | Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml. | — | [ ,
100.0 % Male samples |
Range = [50.0, 69.0] years | European | — | ProtecT | — |
PSS000068 | Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml. | — | [ ,
100.0 % Male samples |
Range = [50.0, 69.0] years | European | — | SEARCH | — |